DeepMed Research

Takeda Pharmaceutical Company Ltd

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma

Phase 4

Active, not recruiting

Conditions: T-Cell Lymphoma

Interventions: Drug: Brentuximab vedotin

First Posted Date: 2022-07-05

Last Posted Date: 2023-09-18

Lead Sponsor: Takeda

Target Recruit Count: 10

Registration Number: NCT05442554

Locations: 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳
Huashan Hospital, Fudan University, Shanghai, Shanghai, China

and more 1 locations

A Proof-of-concept Study to Reduce Treatment Burden in Haemophilia Participants Receiving Factor VIII and Factor IX Infusions

Not Applicable

Completed

Conditions: Hemophilia

Interventions: Device: Virtual-reality (VR) Based Solution

First Posted Date: 2022-06-29

Last Posted Date: 2024-05-06

Lead Sponsor: Takeda

Target Recruit Count: 24

Registration Number: NCT05437211

Locations: 🇫🇷
Hôpital de Hautepierre - Pôle MIRMED, Strasbourg, Alsace-Champagne-Ardenne-Lorraine, France
🇫🇷
Hôpital Hôtel-Dieu, Nantes, Pays De La Loire, France
🇫🇷
CHU Pellegrin, Bordeaux, Nouvelle-Aquitaine, France

and more 3 locations

A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea

Recruiting

Conditions: Inflammatory Bowel Disease (IBD)
Crohn's Disease
Ulcerative Colitis

First Posted Date: 2022-06-23

Last Posted Date: 2024-10-07

Lead Sponsor: Takeda

Target Recruit Count: 600

Registration Number: NCT05428345

Locations: 🇰🇷
Donggguk University Ilsan Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of

A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 Insertion

Completed

Conditions: Non-small Cell Lung Cancer (NSCLC)

First Posted Date: 2022-06-15

Last Posted Date: 2023-09-06

Lead Sponsor: Takeda

Target Recruit Count: 76

Registration Number: NCT05419700

Locations: 🇪🇸
Hospital Universitario de Navarra (HUN), Pamplona, Navarra, Spain
🇪🇸
Hospital Universitario Reina Sofia, Cordoba, Andalucia, Spain
🇪🇸
Hospital Universitario Virgen de la Victoria, Malaga, Andalucia, Spain

and more 12 locations

A Survey of Lanadelumab in Participants with Hereditary Angioedema

Recruiting

Conditions: Hereditary Angioedema (HAE)

Interventions: Drug: Lanadelumab

First Posted Date: 2022-05-31

Last Posted Date: 2025-03-13

Lead Sponsor: Takeda

Target Recruit Count: 100

Registration Number: NCT05397431

Locations: 🇯🇵
Takeda selected site, Tokyo, Japan

A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Poland

Active, not recruiting

Conditions: Inflammatory Bowel Disease (IBD)
Crohn's Disease
Ulcerative Colitis

First Posted Date: 2022-05-20

Last Posted Date: 2024-10-09

Lead Sponsor: Takeda

Target Recruit Count: 165

Registration Number: NCT05384080

Locations: 🇵🇱
Uniwersytecki Szpital Kliniczny, Wroclaw, Dolnoslskie, Poland
🇵🇱
Szpital Uniwersytecki w Krakowie, Krakow, Malopolskie, Poland
🇵🇱
Samodzielny Publiczny Szpital Kliniczny Nr 4 W Lublinie, Lublin, Lubelskie, Poland

and more 8 locations

Maribavir Food-Effect Study in Healthy Adults Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Maribavir

First Posted Date: 2022-05-19

Last Posted Date: 2024-02-16

Lead Sponsor: Takeda

Target Recruit Count: 31

Registration Number: NCT05382104

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada

Completed

Conditions: Short Bowel Syndrome (SBS)

Interventions: Other: Non-interventional Study

First Posted Date: 2022-05-12

Last Posted Date: 2025-04-06

Lead Sponsor: Takeda

Target Recruit Count: 52

Registration Number: NCT05371028

Locations: 🇨🇦
Innomar Strategies, Oakville, Ontario, Canada

A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Completed

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

First Posted Date: 2022-05-05

Last Posted Date: 2023-05-01

Lead Sponsor: Takeda

Target Recruit Count: 6086

Registration Number: NCT05363358

Locations: 🇺🇸
RTI Health Solutions, Durham, North Carolina, United States

A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

Phase 2

Completed

Conditions: Celiac Disease

Interventions: Drug: TAK-062
Dietary Supplement: Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar
Drug: TAK-062 Placebo
Dietary Supplement: Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar

First Posted Date: 2022-04-29

Last Posted Date: 2024-11-28

Lead Sponsor: Takeda

Target Recruit Count: 153

Registration Number: NCT05353985

Locations: 🇺🇸
Medical Associates Research Group, Inc., San Diego, California, United States
🇵🇱
Komisja Bioetyczna przy Okregowej Izbie Lekarskiej w Warszawie, Warszawa, Poland
🇮🇹
Ospedale Umberto I di Torino S.C. Gastroenterologia, Torino, Italy

and more 98 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy